Status:
COMPLETED
An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
Lead Sponsor:
Orasis Pharmaceuticals Ltd.
Conditions:
Presbyopia
Eligibility:
All Genders
40-64 years
Phase:
PHASE3
Brief Summary
This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for ...
Eligibility Criteria
Inclusion
- Subjects must have presbyopia
Exclusion
- Have any contraindications to the study medications or diagnoses that would confound the study data
Key Trial Info
Start Date :
April 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT05393895
Start Date
April 22 2022
End Date
December 1 2022
Last Update
June 11 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Orasis Investigative Site
Newport Beach, California, United States, 92663
2
Orasis Investigative Site
Petaluma, California, United States, 94954
3
Orasis Investigative Site
Colorado Springs, Colorado, United States, 80907
4
Orasis Investigative Site
Danbury, Connecticut, United States, 06810